Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study-Reference-Cited by-同舟云学术

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study

Published:2020-03-25 Issue:6 Volume:16 Page:1292-1298
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Áñez Germán¹^ORCID,Hedrick James²,Simon Michael W.³,Christensen Shane⁴,Jeanfreau Robert⁵,Yau Eddy⁶,Pan Judy⁷,Jordanov Emilia¹,Dhingra Mandeep S.¹^ORCID

Affiliation:

1. Global Clinical Sciences, Sanofi Pasteur, Swiftwater, PA, USA

2. Kentucky Pediatric/Adult Research, Bardstown, KY, USA

3. Private Practice, Nicholasville, KY, USA

4. J. Lewis Research, Salt Lake City, UT, USA

5. MedPharmics, Metairie, LA, USA

6. Global Biostatistical Sciences, Sanofi Pasteur, Toronto, ON, Canada

7. Global Biostatistical Sciences, Sanofi Pasteur, Swiftwater, PA, USA

Funder

Sanofi Pasteur

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1733867

Reference21 articles.

1. Neisseria meningitidis: Biology, Microbiology, and Epidemiology

2. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis

3. Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines

4. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection

5. Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. Centers for Disease Control and Prevention. 2018.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study;Infectious Diseases and Therapy;2024-07-02

2. Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older;Infectious Diseases and Therapy;2023-09-27

3. Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study;Japanese Journal of Infectious Diseases;2023-05-31

4. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion;Expert Review of Vaccines;2023-05-15

5. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study;Pediatric Research;2023-03-10